New Precision Therapies for IPF in Development

  • Research and Development

    New Precision Therapies for IPF in Development

    Posted by Pulmonary Fibrosis News Moderator on July 26, 2018 at 2:23 pm

    NuMedii will collaborate with researchers at Yale School of Medicine and Brigham and Women’s Hospital to develop precision therapies and biomarkers for idiopathic pulmonary fibrosis (IPF).

    Under this strategic research collaboration, the company will work with teams of two leading experts in interstitial lung disease: Naftali Kaminski, MD, a professor of internal medicine and chief of pulmonary, critical care and sleep medicine at Yale School of Medicine, and; Ivan O. Rosas, MD, a physician at Brigham and Women’s Hospital and associate professor at Harvard Medical School.

    Click here to read more about this exciting new collaboration.

    Are you familiar with these researchers and their work? What are your thoughts on this news?

    replied 5 years, 9 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .